← Back to Search

CAR T-cell Therapy

Long-Term Follow-Up of P-BCMA-101 for Multiple Myeloma

Phase 1
Waitlist Available
Research Sponsored by Poseida Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable
Awards & highlights

Study Summary

This trial will follow subjects for 15 years to assess long-term safety and effectiveness of P-BCMA-101 T cells. Rimiducid may be given as needed.

Who is the study for?
This trial is for individuals who have previously received P-BCMA-101 T cell treatment for multiple myeloma, either completing or discontinuing early from a Poseida sponsored study. Participants must consent to long-term follow-up.Check my eligibility
What is being tested?
The study monitors the safety and effectiveness of P-BCMA-101 T cells over 15 years post-treatment. It evaluates the risk of delayed side effects, ongoing benefits, and tracks levels of these specialized T cells in subjects.See study design
What are the potential side effects?
While specific side effects are not listed, this trial will assess any delayed adverse events related to P-BCMA-101 T cell therapy that may occur over the long term.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable
This trial's timeline: 3 weeks for screening, Varies for treatment, and rimiducid infusion through year 15 after p-bcma-101 infusion, if applicable for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary outcome measures
Anti-myeloma effect of P-BCMA-101 (Duration of Response)
Anti-myeloma effect of P-BCMA-101 (Overall Survival)
Anti-myeloma effect of P-BCMA-101 (Progression Free Survival)
+8 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: P-BCMA-101 treatedExperimental Treatment1 Intervention
Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.

Find a Location

Who is running the clinical trial?

Poseida Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
596 Total Patients Enrolled
2 Trials studying Multiple Myeloma
336 Patients Enrolled for Multiple Myeloma
California Institute for Regenerative Medicine (CIRM)OTHER
62 Previous Clinical Trials
3,053 Total Patients Enrolled
1 Trials studying Multiple Myeloma
105 Patients Enrolled for Multiple Myeloma
Rajesh Belani, M.D.Study DirectorSponsor Executive Medical Director
4 Previous Clinical Trials
496 Total Patients Enrolled
2 Trials studying Multiple Myeloma
336 Patients Enrolled for Multiple Myeloma

Media Library

P-BCMA-101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03741127 — Phase 1
Multiple Myeloma Research Study Groups: P-BCMA-101 treated
Multiple Myeloma Clinical Trial 2023: P-BCMA-101 Highlights & Side Effects. Trial Name: NCT03741127 — Phase 1
P-BCMA-101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03741127 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this therapy backed by any prior experimental investigations?

"Currently, 16 trials are running that aim to assess the efficacy of this treatment with none reaching Phase 3 yet. Even though most studies take place in Nashville, Tennessee, 94 different sites across the country have joined these investigations."

Answered by AI

How many participants have thus far volunteered for the clinical trial?

"This clinical trial has unfortunately ended its recruitment period. It was posted on October 29th 2018 and the last update occurred June 30th 2022, rendering it no longer available for patient registration. However, 805 other studies related to multiple myeloma are still actively seeking participants, 16 of which involve this specific treatment."

Answered by AI

Are there still openings available to join this clinical trial?

"According to the clinicaltrials.gov database, this trial is not currently open for recruitment. It was initially posted on October 29th 2018 and its most recent update occurred on June 30th 2022. Although this study does not require new candidates at present, 821 other trials are actively seeking participants now."

Answered by AI

Has this medical experiment been extended to various facilities across North America?

"This clinical trial is currently underway at 16 distinct sites, including San Diego, Hackensack and Gilbert. To reduce the strain of travel on participants, it is important to select a location close to their residence if they decide to enroll."

Answered by AI

Has this therapeutic intervention been sanctioned by the Federal Drug Administration?

"Due to the limited amount of data available on safety and efficacy, this treatment has been rated as a 1 in terms of security."

Answered by AI
~61 spots leftby Aug 2032